All In Biotech

Drug Trial Radar · NCT06160609

Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMM

A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Anti-Cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)-DREAMM5. Sub-study 1 - Belantamab Mafodotin and aOX40 (GSK3174998) in Combination

Last checked: Nov 20, 2026Latest source record: Mar 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

9

Actual

Start

Oct 7, 2019

Primary completion

Jan 9, 2023

Study completion Jan 9, 2023

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Dec 7, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose is to determine the safety and tolerability of belantamab mafodotin in combination with other anti-cancer treatments (in each sub-study), and to establish the recommended Phase 2 dose for each combination treatment to explore in the cohort expansion phase. This study is the sub study of the Master protocol (NCT04126200).

Conditions

  • Relapsed/Refractory Multiple Myeloma

Interventions

  • Belantamab MafodotinDrug

    Belantamab Mafodotin will be administered.

  • GSK3174998Drug

    GSK3174998 will be administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. DE Phase: Number of Participants With Dose Limiting Toxicities (DLT)Time frame: Up to 21 days
  2. DE Phase: Number of Participants With Adverse Events (AEs)Time frame: Up to 170 weeks
  3. DE Phase: Number of Participants With Worst-Case Hematology Results by Maximum Grade Increase Post - Baseline Relative to BaselineTime frame: Baseline (Day 1) and up to 170 weeks
  4. DE Phase: Number of Participants With Worst-Case Chemistry Results by Maximum Grade Increase Post - Baseline Relative to BaselineTime frame: Baseline (Day 1) and up to 170 weeks
  5. Cohort Expansion (CE) Phase: Overall Response Rate (ORR)Time frame: Up to 170 weeks

Locations

3 sites in 3 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Fitzroy, Victoria, Australia

  • GSK Investigational Site

    Toronto, Ontario, Canada

  • GSK Investigational Site

    Stockholm, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.